Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Skin and bone: a mysterious link to an underdiagnosed cause of osteonecrosis.

EULAR rheumatology open·2026
Same author

Professional positioning of general practitioners in the management of postmenopausal osteoporosis in community medicine.

EULAR rheumatology open·2026
Same author

Relapse risk of lupus-related serositis according to immunosuppressive therapy: a national real-world study.

RMD open·2026
Same author

Inviting ecosystems into the exposome framework.

Exposome·2026
Same author

Acute myocarditis after switching between two adalimumab biosimilars.

Rheumatology (Oxford, England)·2026
Same author

Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series.

Annals of the rheumatic diseases·2026
Same journal

Greater trochanteric bursal distension with intra-bursal rice bodies: an unusual MRI presentation.

Joint bone spine·2026
Same journal

Evaluating the Impact of a Rheumatologist-led Comorbidity Review in Patients with Inflammatory Arthritis.

Joint bone spine·2026
Same journal

What cumulative glucocorticoid dose should trigger sparing strategies in polymyalgia rheumatica?

Joint bone spine·2026
Same journal

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update.

Joint bone spine·2026
Same journal

Multimodal imaging evaluation of the entheses in spondyloarthritis.

Joint bone spine·2026
Same journal

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update. What's new?

Joint bone spine·2026
See all related articles

Related Experiment Video

Updated: May 18, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Acute hepatitis E during biotherapy.

Hélène Bauer1, Jean Sibilia, Paul Moreau

  • 1Internal medicine E and rheumatology department, hôpitaux civils de Colmar, 39, avenue de la Liberté, 68000 Colmar, France.

Joint Bone Spine
|September 25, 2012
PubMed
Summary
This summary is machine-generated.

Hepatitis E is usually mild but can be severe in immunocompromised individuals. This case highlights a potential risk in rheumatoid arthritis patients on biological agents.

More Related Videos

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Experiment Videos

Last Updated: May 18, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Area of Science:

  • Hepatology
  • Immunology
  • Rheumatology

Background:

  • Hepatitis E virus (HEV) infection is typically self-limiting.
  • HEV incidence is increasing in France.
  • Immunocompromised patients are at risk for severe or chronic HEV.

Observation:

  • A case of hepatitis E is presented.
  • The patient had rheumatoid arthritis.
  • The patient was undergoing immunosuppressive therapy with a biological agent.

Findings:

  • The patient developed hepatitis E.
  • This demonstrates a potential complication of immunosuppressive therapy for rheumatoid arthritis.

Implications:

  • Clinicians should consider HEV in immunocompromised patients with rheumatoid arthritis presenting with liver abnormalities.
  • Monitoring for HEV may be warranted in this patient population.
  • Further research into HEV risk in patients on biological agents is needed.